Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EPO906 epothilone B · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| EPO906 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| EPO906 epothilone B | DRUG | - |
Inclusion Criteria: * Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progre...
EPO906 epothilone B is an investigational small molecule being studied for the treatment of carcinoid and other neuroendocrine tumors. It is in Phase 2 clinical development and has not been approved by regulatory authorities.
EPO906 epothilone B is an epothilone, a class of microtubule-stabilizing agents. It works by binding to tubulin and stabilizing microtubules, which disrupts cell division and can lead to cancer cell death.
EPO906 epothilone B is being developed by Novartis AG, a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker symbol NVS.
EPO906 epothilone B is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency.
EPO906 epothilone B has been studied in one completed Phase 2 clinical trial, NCT00050349, titled 'EPO906 in Carcinoid and Other Neuroendocrine Tumors.' This trial enrolled 33 participants in the United States and was not randomized or blinded.